Zytiga has highest market share in Prostate Cancer Market share globally. Zytiga is facing hard fight from Xtandi drugs which is anticipated to substitute Zytiga as the primary prostate cancer drugs in 2015. Zytiga was one of a small number of treatment choices for patients suffering from prostate cancer. This shows that most doctors prefer to treat patients with Zytiga drug despite its side effects. Before September 10, 2014 Xtandi, was given to only those patients who have previously received chemotherapy. But after September 10, 2014, Xtandi was permitted to be used as treatment choice for pre–chemotherapy prostate cancer patients.
Out of 15 Prostate Drugs Market share only 4 drugs (Zytiga, Zoladex, Leuplin & Xtandi or MDV3100) have double digit market share in prostate cancer drugs market. All these four drugs together account for more than 60 percent market share. Zytiga market share is more than double from its nearest competitor Leuplin.